A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE	PAT	IENT ID	: 1763868
COLLECTED BY	:	REG	. NO./LAB NO.	: 122502200019
REFERRED BY	:	REG	ISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COL	LECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITU	TE Rep	ORTING DATE	: 20/Feb/2025 01:52PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBAL	A CITY - HARYAN	JA	
Test Name		Value	Unit	Biological Reference interval
	SWASTI	HYA WELLN	ESS PANEL: 1.5	
	СОМР	LETE BLOOD	COUNT (CBC)	
RED BLOOD CELLS	(RBCS) COUNT AND INDICES			
HAEMOGLOBIN (H)	B)	13.2	gm/dL	12.0 - 16.0
RED BLOOD CELL (by hydro dynamic f	RBC) COUNT OCUSING, ELECTRICAL IMPEDENCE	5.15 ^H	Millions/cr	
-	UTOMATED HEMATOLOGY ANALYZER	38.7	%	37.0 - 50.0
-	UTOMATED HEMATOLOGY ANALYZER	75.1 ^L	fL	80.0 - 100.0
by CALCULATED BY A	AR HAEMOGLOBIN (MCH) UTOMATED HEMATOLOGY ANALYZER	25.7 ^L	pg	27.0 - 34.0
by CALCULATED BY A	AR HEMOGLOBIN CONC. (MCHC) UTOMATED HEMATOLOGY ANALYZER	34.2	g/dL	32.0 - 36.0
by CALCULATED BY A	UTION WIDTH (RDW-CV) UTOMATED HEMATOLOGY ANALYZER	13.3	%	11.00 - 16.00
by CALCULATED BY A	UTION WIDTH (RDW-SD) UTOMATED HEMATOLOGY ANALYZER	37.9	fL	35.0 - 56.0
MENTZERS INDEX by CALCULATED		14.58	RATIO	BETA THALASSEMIA TRAIT: 13.0 IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING IND		19.45	RATIO	BETA THALASSEMIA TRAIT:< 65.0 IRON DEFICIENCY ANEMIA: > 65.0
WHITE BLOOD CE		0.400	,	1000 11000
	COUNT (TLC) / by sf cube & microscopy UCOCYTE COUNT (DLC)	8490	/cmm	4000 - 11000
NEUTROPHILS	' BY SF CUBE & MICROSCOPY	57	%	50 - 70
LYMPHOCYTES		33	%	20 - 40

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE



【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE		PATIENT ID	: 1763868
COLLECTED BY	:		REG. NO./LAB NO.	: 122502200019
REFERRED BY	:		REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134		COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INST	TITUTE	REPORTING DATE	: 20/Feb/2025 01:52PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AM	IBALA CITY - H	IARYANA	
Test Name		Value	Unit	Biological Reference interval
by FLOW CYTOMETR	Y BY SF CUBE & MICROSCOPY			
EOSINOPHILS by FLOW CYTOMETR	Y BY SF CUBE & MICROSCOPY	4	%	1 - 6
MONOCYTES by FLOW CYTOMETR	Y BY SF CUBE & MICROSCOPY	6	%	2 - 12
DACODIUC		0	0/	0 1

BASOPHILS	0	%	0 - 1
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE LEUKOCYTES (WBC) COUNT			
ABSOLUTE NEUTROPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	4839	/cmm	2000 - 7500
ABSOLUTE LYMPHOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	2802	/cmm	800 - 4900
ABSOLUTE EOSINOPHIL COUNT by flow cytometry by SF cube & microscopy	340	/cmm	40 - 440
ABSOLUTE MONOCYTE COUNT by flow cytometry by sf cube & microscopy	509	/cmm	80 - 880
ABSOLUTE BASOPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	/cmm	0 - 110
PLATELETS AND OTHER PLATELET PREDICTIVE	MARKERS.		
PLATELET COUNT (PLT) by hydro dynamic focusing, electrical impedence	207000	/cmm	150000 - 450000
PLATELETCRIT (PCT) by hydro dynamic focusing, electrical impedence	0.26	%	0.10 - 0.36
MEAN PLATELET VOLUME (MPV) by hydro dynamic focusing, electrical impedence	12	fL	6.50 - 12.0
PLATELET LARGE CELL COUNT (P-LCC) by hydro dynamic focusing, electrical impedence	98000 ^H	/cmm	30000 - 90000
PLATELET LARGE CELL RATIO (P-LCR) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	47.2 ^H	%	11.0 - 45.0
	10.0	%	15.0 - 17.0
PLATELET DISTRIBUTION WIDTH (PDW) by hydro dynamic focusing, electrical impedence NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD	16.3	70	13.0 - 17.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST





🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE	PATI	ENT ID	: 1763868
COLLECTED BY	:	REG.	NO./LAB NO.	: 122502200019
REFERRED BY	:	REGI	STRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COLL	ECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE IN	ISTITUTE REPO	RTING DATE	: 20/Feb/2025 05:16PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, A	AMBALA CITY - HARYANA	Α	
Test Name		Value	Unit	Biological Reference interval
	GL	YCOSYLATED HAEMO	GLOBIN (HBA1C)	
GLYCOSYLATED HAE WHOLE BLOOD	MOGLOBIN (HbA1c):	5.6	%	4.0 - 6.4
ESTIMATED AVERAG		114.02	mg/dL	60.00 - 140.00
	AS PER AMERICAN DIA	ABETES ASSOCIATION (ADA):		
	FERENCE GROUP	GLYCOSYLATED	HEMOGLOGIB (HBAIC) in %	
	etic Adults >= 18 years		<5.7	
	Risk (Prediabetes)	<u>DIVE</u>	5.7 – 6.4	
Diag	gnosing Diabetes		>= 6.5	
		Goals of Therapy:	e > 19 Years < 7.0	
Therapeutic	goals for glycemic control	Actions Suggested:	>8.0	
			je < 19 Years	

COMMENTS:

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.

2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be 4.High appropiate.

HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.






DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

Test Name	Value	Unit	Biological Reference interval
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY	- HARYANA	
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 20/Feb/2025 05:16PM
BARCODE NO.	: 12507134	COLLECTION DATE	: 20/Feb/2025 11:54AM
REFERRED BY	:	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
COLLECTED BY	:	REG. NO./LAB NO.	: 122502200019
AGE/ GENDER	: 69 YRS/FEMALE	PATIENT ID	: 1763868
NAME	: Mrs. NEELAM KHANNA		







DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST





🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE	PAT	FIENT ID	: 1763868
COLLECTED BY	:	REG	G. NO./LAB NO.	: 122502200019
REFERRED BY	:	REG	GISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COI	LECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTIT	UTE REI	PORTING DATE	: 20/Feb/2025 04:45PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBA	ALA CITY - HARYA	NA	
Test Name		Value	Unit	Biological Reference interval
	ERYTHROC	YTE SEDIME	NTATION RATE (1	ESR)
by RED CELL AGGRE	ERYTHROC DIMENTATION RATE (ESR) GATION BY CAPILLARY PHOTOMETRY	CYTE SEDIMEN 23 ^H	NTATION RATE (1 mm/1st	,
by RED CELL AGGREC	DIMENTATION RATE (ESR) GATION BY CAPILLARY PHOTOMETRY	23 ^H	mm/1st	hr 0 - 20
by RED CELL AGGREC INTERPRETATION: 1. ESR is a non-specif immune disease, but	DIMENTATION RATE (ESR) GATION BY CAPILLARY PHOTOMETRY ic test because an elevated result of does not tell the health practitioner	23 ^H ten indicates the p exactly where the	mm/1st presence of inflammati e inflammation is in the	hr 0 - 20 ion associated with infection, cancer and auto body or what is causing it.
by RED CELL AGGREC INTERPRETATION: 1. ESR is a non-specifimmune disease, but 2. An ESR can be affe	DIMENTATION RATE (ESR) GATION BY CAPILLARY PHOTOMETRY ic test because an elevated result of does not tell the health practitioner	23 ^H ten indicates the p exactly where the	mm/1st presence of inflammati e inflammation is in the	hr 0 - 20 ion associated with infection, cancer and auto body or what is causing it.
by RED CELL AGGREC INTERPRETATION: 1. ESR is a non-specifi immune disease, but 2. An ESR can be affe as C-reactive protein 3. This test may also	DIMENTATION RATE (ESR) GATION BY CAPILLARY PHOTOMETRY ic test because an elevated result of does not tell the health practitioner cted by other conditions besides infl be used to monitor disease activity a	23 ^H ten indicates the p exactly where the ammation. For thi	mm/1st presence of inflammati inflammation is in the s reason, the ESR is typ	hr 0 - 20
by RED CELL AGGREC INTERPRETATION: 1. ESR is a non-specifi immune disease, but 2. An ESR can be affe as C-reactive protein 3. This test may also systemic lupus erythe	DIMENTATION RATE (ESR) GATION BY CAPILLARY PHOTOMETRY ic test because an elevated result of does not tell the health practitioner cted by other conditions besides infl be used to monitor disease activity a ematosus	23 ^H ten indicates the p exactly where the ammation. For thi	mm/1st presence of inflammati inflammation is in the s reason, the ESR is typ	hr 0 - 20 ion associated with infection, cancer and auto body or what is causing it. pically used in conjunction with other test suc
by RED CELL AGGREC INTERPRETATION: 1. ESR is a non-specifimmune disease, but 2. An ESR can be affe as C-reactive protein 3. This test may also systemic lupus erythe CONDITION WITH LOV A low ESR can be see	DIMENTATION RATE (ESR) GATION BY CAPILLARY PHOTOMETRY ic test because an elevated result of does not tell the health practitioner cted by other conditions besides infl be used to monitor disease activity a ematosus N ESR n with conditions that inhibit the no	23 ^H ten indicates the p exactly where the ammation. For thi and response to the rmal sedimentation	mm/1st	hr 0 - 20 ion associated with infection, cancer and auto a body or what is causing it. bically used in conjunction with other test suc bove diseases as well as some others, such as

NOTE:

1. ESR and C - reactive protein (C-RP) are both markers of inflammation.

2. Generally, ESR does not change as rapidly as does CRP, either at the start of inflammation or as it resolves.
 3. CRP is not affected by as many other factors as is ESR, making it a better marker of inflammation.
 4. If the ESR is elevated, it is typically a result of two types of proteins, globulins or fibrinogen.
 5. Women tend to have a higher ESR, and menstruation and pregnancy can cause temporary elevations.
 4. Drugs such as devicent matching and units of two types of proteins and units of the temporary elevations.

6. Drugs such as dextran, methyldopa, oral contraceptives, penicillamine procainamide, theophylline, and vitamin A can increase ESR, while aspirin, cortisone, and quinine may decrease it





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

TEST PERFORMED AT KOS DIAGNOSTIC LAB. AMBALA CANTT



A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE	PA	TIENT ID	: 1763868
COLLECTED BY	:	RE	EG. NO./LAB NO.	: 122502200019
REFERRED BY	:	RE	GISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	CO	LLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE IN	ISTITUTE RE	PORTING DATE	: 20/Feb/2025 01:52PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, A	AMBALA CITY - HARYA	ANA	
Test Name		Value	Unit	Biological Reference interval
	CLINI	ICAL CHEMISTR	RY/BIOCHEMIST	'RY
		GLUCOSE FA	STING (F)	
GLUCOSE FASTING by glucose oxidas	G (F): PLASMA e - peroxidase (god-pod)	81.8	mg/dL	NORMAL: < 100.0 PREDIABETIC: 100.0 - 125.0 DIABETIC: > 0R = 126.0
INTERPRETATION				

A fasting plasma glucose level below 100 mg/dl is considered normal.
 A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood test (after consumption of 75 gms of glucose) is recommended for all such patients.
 A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients.
 A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE		PATIENT ID	: 1763868
COLLECTED BY	:		REG. NO./LAB NO.	: 122502200019
REFERRED BY	:		REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134		COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INS	STITUTE	REPORTING DATE	: 20/Feb/2025 01:52PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, A	MBALA CITY - HA	RYANA	
Test Name		Value	Unit	Biological Reference interval
		LIPID PR	OFILE : BASIC	
CHOLESTEROL TO' by CHOLESTEROL O		275.79 ^H	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: S by GLYCEROL PHOSF	ERUM PHATE OXIDASE (ENZYMATIC)	208.19 ^H	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTERO by SELECTIVE INHIBIT	L (DIRECT): SERUM 70N	50.84	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTERO		183.31 ^H	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129. BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLES' by Calculated, spe		224.95 ^H	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159. BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTER(41.64	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SEF by CALCULATED, SPE		759.77 ^H	mg/dL	350.00 - 700.00
CHOLESTEROL/HI by CALCULATED, SPE		5.42 ^H	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE



🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA		
AGE/ GENDER	: 69 YRS/FEMALE	PATIENT ID	: 1763868
COLLECTED BY	:	REG. NO./LAB NO.	: 122502200019
REFERRED BY	:	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 20/Feb/2025 01:52PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY -	HARYANA	

Test Name	Value	Unit	Biological Reference interval
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	3.61 ^H	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	4.1	RATIO	3.00 - 5.00

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





A PIONEER DIAGNOSTIC CENTRE

🕻 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE]	PATIENT ID	: 1763868
COLLECTED BY	:]	REG. NO./LAB NO.	: 122502200019
REFERRED BY	:]	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	(COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTIT	UTE	REPORTING DATE	: 20/Feb/2025 01:52PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBA	ALA CITY - HAR	CYANA	
Test Name		Value	Unit	Biological Reference interval
	LIVER	FUNCTION	TEST (COMPLETE)	
BILIRUBIN TOTAL by diazotization, si	: SERUM PECTROPHOTOMETRY	0.48	mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20
	C (CONJUGATED): SERUM	0.14	mg/dL	0.00 - 0.40
BILIRUBIN INDIRE by CALCULATED, SPE	CT (UNCONJUGATED): SERUM	0.34	mg/dL	0.10 - 1.00
SGOT/AST: SERUM by IFCC, WITHOUT PY	RIDOXAL PHOSPHATE	22.49	U/L	7.00 - 45.00
SGPT/ALT: SERUM by IFCC, WITHOUT PY	RIDOXAL PHOSPHATE	21.36	U/L	0.00 - 49.00
AST/ALT RATIO: S by CALCULATED, SPE		1.05	RATIO	0.00 - 46.00
ALKALINE PHOSPI	HATASE: SERUM yl phosphatase by amino methyl	99.66	U/L	40.0 - 130.0

by PARA NITROPHENYL PHOSPHATASE BY AMINO METHYL PROPANOL	33.00	0/1	40.0 - 130.0
GAMMA GLUTAMYL TRANSFERASE (GGT): SERUM by szasz, spectrophtometry	22.44	U/L	0.00 - 55.0
TOTAL PROTEINS: SERUM by BIURET, SPECTROPHOTOMETRY	6.53	gm/dL	6.20 - 8.00
ALBUMIN: SERUM by BROMOCRESOL GREEN	4.18	gm/dL	3.50 - 5.50
GLOBULIN: SERUM by calculated, spectrophotometry	2.35	gm/dL	2.30 - 3.50
A : G RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.78	RATIO	1.00 - 2.00

INTERPRETATION

NOTE:- To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range. USE: - Differential diagnosis of diseases of hepatobiliary system and pancreas.

INCREASED:

DRUG HEPATOTOXICITY	> 2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5
HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS	> 1.3 (Slightly Increased)





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST





【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA		
AGE/ GENDER	: 69 YRS/FEMALE	PATIENT ID	: 1763868
COLLECTED BY	:	REG. NO./LAB NO.	: 122502200019
REFERRED BY	:	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 20/Feb/2025 01:52PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY -	HARYANA	

DECREASED:

1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)

2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST





A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE		PATIENT ID	: 1763868
COLLECTED BY	:		REG. NO./LAB NO.	: 122502200019
REFERRED BY	:		REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134		COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INST	ITUTE	REPORTING DATE	: 20/Feb/2025 05:05PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AM	BALA CITY - H	IARYANA	
Test Name		Value	Unit	Biological Reference interval
	KIDNI	EY FUNCTI	ON TEST (COMPLETE))
UREA: SERUM by UREASE - GLUTAM	IATE DEHYDROGENASE (GLDH)	25.71	mg/dL	10.00 - 50.00
CREATININE: SERU		0.98	mg/dL	0.40 - 1.20
BLOOD UREA NITR by CALCULATED, SPE	COGEN (BUN): SERUM	12.01	mg/dL	7.0 - 25.0
PLOOD LIDEA NITE	OCEN (DUN) (CDEATININE	12.26	DATIO	10.0 20.0

restrame	Value	Unit	biological weier ence inter var
KIDNI	EY FUNCTION TE	ST (COMPLETE)	
UREA: SERUM	25.71	mg/dL	10.00 - 50.00
by UREASE - GLUTAMATE DEHYDROGENASE (GLDH)		Ũ	
CREATININE: SERUM by ENZYMATIC, SPECTROPHOTOMETERY	0.98	mg/dL	0.40 - 1.20
BLOOD UREA NITROGEN (BUN): SERUM by CALCULATED, SPECTROPHOTOMETRY	12.01	mg/dL	7.0 - 25.0
BLOOD UREA NITROGEN (BUN)/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	12.26	RATIO	10.0 - 20.0
UREA/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	26.23	RATIO	
URIC ACID: SERUM by URICASE - OXIDASE PEROXIDASE	4.42	mg/dL	2.50 - 6.80
CALCIUM: SERUM by ARSENAZO III, SPECTROPHOTOMETRY	9.62	mg/dL	8.50 - 10.60
PHOSPHOROUS: SERUM by PHOSPHOMOLYBDATE, SPECTROPHOTOMETRY	3.33	mg/dL	2.30 - 4.70
<u>ELECTROLYTES</u>			
SODIUM: SERUM by ISE (ION SELECTIVE ELECTRODE)	141.4	mmol/L	135.0 - 150.0
POTASSIUM: SERUM by ISE (ION SELECTIVE ELECTRODE)	4.6	mmol/L	3.50 - 5.00
CHLORIDE: SERUM by ISE (ION SELECTIVE ELECTRODE)	106.05	mmol/L	90.0 - 110.0
ESTIMATED GLOMERULAR FILTERATION RATE			
ESTIMATED GLOMERULAR FILTERATION RATE (eGFR): SERUM by CALCULATED	62.5		
INTERPRETATION: To differentiate between pre- and post renal azotemia.			

INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.

2. Catabolic states with increased tissue breakdown.

3. GI haemorrhage.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA		
AGE/ GENDER	: 69 YRS/FEMALE	PATIENT ID	: 1763868
COLLECTED BY	:	REG. NO./LAB NO.	: 122502200019
REFERRED BY	:	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 20/Feb/2025 05:05PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CIT	Y - HARYANA	
Test Name	Valu	ue Unit	Biological Reference interval
4. High protein intake	<u>.</u>		
5. Impaired renal fur	nction plus		
		infection, GI bleeding, thyrotoxic	osis, Cushing's syndrome, high protein diet,
burns, surgery, cache			
	n (e.g. ureter colostomy)		
	nass (subnormal creatinine production)		
	tetracycline, glucocorticoids)		
INCREASED RATIO (>2	20:1) WITH ELEVATED CREATININE LEVELS:		

1. Postrenal azotemia (BUN rises disproportionately more than creatinine) (e.g. obstructive uropathy).

2. Prerenal azotemia superimposed on renal disease.

DECREASED RATIO (<10:1) WITH DECREASED BUN :

1. Acute tubular necrosis.

2. Low protein diet and starvation.

3. Severe liver disease.

4. Other causes of decreased urea synthesis.

5. Repeated dialysis (urea rather than creatinine diffuses out of extracellular fluid).

6. Inherited hyperammonemias (urea is virtually absent in blood).

7. SIADH (syndrome of inappropiate antidiuretic harmone) due to tubular secretion of urea.

8. Pregnancy.

DECREASED RATIO (<10:1) WITH INCREASED CREATININE:

1. Phenacimide therapy (accelerates conversion of creatine to creatinine).

2. Rhabdomyolysis (releases muscle creatinine).

3. Muscular patients who develop renal failure.

INAPPROPIATE RATIO:

1. Diabetic ketoacidosis (acetoacetate causes false increase in creatinine with certain methodologies, resulting in normal ratio when dehydration should produce an increased BUN/creatinine ratio).

2. Cephalosporin therapy (interferes with creatinine measurement).

CKD STAGE	DESCRIPTION	GFR (mL/min/1.73m2)	ASSOCIATED FINDINGS
G1	Normal kidney function	>90	No proteinuria
G2	Kidney damage with normal or high GFR	>90	Presence of Protein , Albumin or cast in urine
G3a	Mild decrease in GFR	60 -89	
G3b	Moderate decrease in GFR	30-59	
G4	Severe decrease in GFR	15-29	
G5	Kidney failure	<15	



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA		
AGE/ GENDER	: 69 YRS/FEMALE	PATIENT ID	: 1763868
COLLECTED BY	:	REG. NO./LAB NO.	: 122502200019
REFERRED BY	:	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 20/Feb/2025 05:05PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - H	IARYANA	

Test Name	Value	Unit	Biological Reference interval

COMMENTS:

1. Estimated Glomerular filtration rate (eGFR) is the sum of filtration rates in all functioning nephrons and so an estimation of the GFR provides a measure of functioning nephrons of the kidney. 2. eGFR calculated using the 2009 CKD-EPI creatinine equation and GFR category reported as per KDIGO guideline 2012

3. In patients, with eGFR creatinine between 45-59 ml/min/1.73 m2 (G3) and without any marker of Kidney damage, It is recommended to measure eGFR with Cystatin C for confirmation of CKD

4. eGFR category G1 OR G2 does not fullfill the criteria for CKD, in the absence of evidence of Kidney Damage 5. In a suspected case of Acute Kidney Injury (AKI), measurement of eGFR should be done after 48-96 hours of any Intervention or procedure 6. eGFR calculated by Serum Creatinine may be less accurate due to certain factors like Race, Muscle Mass, Diet, Certain Drugs. In such cases, eGFR should be calculated using Serum Cystatin C 7. A decrease in eGFR implies either progressive renal disease, or a reversible process causing decreased nephron function (eg, severe dehydration).

ADVICE:

KDIGO guideline, 2012 recommends Chronic Kidney Disease (CKD) should be classified based on cause, eGFR category and Albuminuria (ACR) category. GFR & ACR category combined together reflect risk of progression and helps Clinician to identify the individual who are progressing at more rapid rate than anticipated



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA		
AGE/ GENDER	: 69 YRS/FEMALE	PATIENT ID	: 1763868
COLLECTED BY	:	REG. NO./LAB NO.	: 122502200019
REFERRED BY	:	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 20/Feb/2025 05:11PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - H	HARYANA	
Test Name	Value	Unit	Biological Reference interva

	IRON PR	OFILE	
IRON: SERUM by FERROZINE, SPECTROPHOTOMETRY	73.1	μg/dL	37.0 - 145.0
UNSATURATED IRON BINDING CAPACITY (UIBC :SERUM by FERROZINE, SPECTROPHOTOMETERY) 291.85	µg/dL	150.0 - 336.0
TOTAL IRON BINDING CAPACITY (TIBC) :SERUM by SPECTROPHOTOMETERY	364.95	µg/dL	230 - 430
%TRANSFERRIN SATURATION: SERUM by CALCULATED, SPECTROPHOTOMETERY (FERENE)	20.03	%	15.0 - 50.0
TRANSFERRIN: SERUM by SPECTROPHOTOMETERY (FERENE)	259.11	mg/dL	200.0 - 350.0
INTERPRETATION:-			THALACCEANA ~ /2 TOAT

VARIABLES	ANEMIA OF CHRONIC DISEASE	IRON DEFICIENCY ANEMIA	THALASSEMIA α/β TRAIT
SERUM IRON:	Normal to Reduced	Reduced	Normal
TOTAL IRON BINDING CAPACITY:	Decreased	Increased	Normal
% TRANSFERRIN SATURATION:	Decreased	Decreased < 12-15 %	Normal
SERUM FERRITIN:	Normal to Increased	Decreased	Normal or Increased
IDON.			

IRON:

1.Serum iron studies is recommended for differential diagnosis of microcytic hypochromic anemia.i.e iron deficiency anemia, zinc deficiency anemia, anemia of chronic disease and thalassemia syndromes.

It is essential to isolate iron deficiency anemia from Beta thalassemia syndromes because during iron replacement which is therapeutic for iron deficiency anemia, is severely contra-indicated in Thalassemia.
 TOTAL IRON BINDING CAPACITY (TIBC):

1.It is a direct measure of protein transferrin which transports iron from the gut to storage sites in the bone marrow. % TRANSFERRIN SATURATION:

1. Occurs in idiopathic hemochromatosis and transfusional hemosiderosis where no unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of transferrin.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE	PAT	IENT ID	: 1763868
COLLECTED BY	:	REG.	. NO./LAB NO.	: 122502200019
REFERRED BY	:	REG	ISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COLL	LECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUT	TE REP	ORTING DATE	: 20/Feb/2025 01:52PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBAL	A CITY - HARYAN	IA	
Test Name		Value	Unit	Biological Reference interva
Test Name				Biological Reference interva
Test Name		ENDOCRIN	OLOGY	Biological Reference interva
	THYRO	ENDOCRIN	OLOGY N TEST: TOTAL	U
TRIIODOTHYRONII	THYRO	ENDOCRIN	OLOGY	Biological Reference interva 0.35 - 1.93
TRIIODOTHYRONII by CMIA (CHEMILUMIN THYROXINE (T4): S	THYRO NE (T3): SERUM MESCENT MICROPARTICLE IMMUNOASSAY) SERUM	ENDOCRIN	OLOGY N TEST: TOTAL	U
TRIIODOTHYRONII by CMIA (CHEMILUMIN THYROXINE (T4): S by CMIA (CHEMILUMIN THYROID STIMULA	THYRO NE (T3): SERUM iescent microparticle immunoassay) SERUM iescent microparticle immunoassay) NTING HORMONE (TSH): SERUM	ENDOCRIN DID FUNCTION 1.27	OLOGY N TEST: TOTAL ng/mL	0.35 - 1.93
TRIIODOTHYRONII by CMIA (CHEMILUMIN THYROXINE (T4): S by CMIA (CHEMILUMIN THYROID STIMULA	THYRO NE (T3): SERUM IESCENT MICROPARTICLE IMMUNOASSAY) SERUM IESCENT MICROPARTICLE IMMUNOASSAY) NTING HORMONE (TSH): SERUM IESCENT MICROPARTICLE IMMUNOASSAY)	ENDOCRIN DID FUNCTION 1.27 7.23	OLOGY N TEST: TOTAL ng/mL µgm/dL	0.35 - 1.93 4.87 - 12.60

TSH levels are subject to circadian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50%. Hence time of the day has influence on the measured serum TSH concentrations. TSH stimulates the production and secretion of the metabolically active hormones, thyroxine (T4) and triiodothyronine (T3). Failure at any level of regulation of the hypothalamic-pituitary-thyroid axis will result in either underproduction (hypothyroidism) or overproduction(hyperthyroidism) of T4 and/or T3.

CLINICAL CONDITION	Т3	T4	TSH
Primary Hypothyroidism:	Reduced	Reduced	Increased (Significantly)
Subclinical Hypothyroidism:	Normal or Low Normal	Normal or Low Normal	High
Primary Hyperthyroidism:	Increased	Increased	Reduced (at times undetectable)
Subclinical Hyperthyroidism:	Normal or High Normal	Normal or High Normal	Reduced

LIMITATIONS:-

1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG), and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests.

2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs (e.g.: phenytoin , salicylates).

3. Serum T4 levels in neonates and infants are higher than values in the normal adult , due to the increased concentration of TBG in neonate serum.

4. TSH may be normal in central hypothyroidism , recent rapid correction of hyperthyroidism or hypothyroidism , pregnancy , phenytoin therapy.

TRIIODOTH	YRONINE (T3)	THYROXINE (T4)		THYROID STIMULATING HORMONE (TSH)		
Age	Refferance Range (ng/mL)	Age	Refferance Range (µg/dL)	Age	Reference Range (µIU/mL)	
0-7 Days	0.20 - 2.65	0 - 7 Days	5.90 - 18.58	0 - 7 Days	2.43 - 24.3	
7 Days - 3 Months	0.36 - 2.59	7 Days - 3 Months	6.39 - 17.66	7 Days - 3 Months	0.58 - 11.00	
3 - 6 Months	0.51 - 2.52	3 - 6 Months	6.75 – 17.04	3 Days – 6 Months	0.70 - 8.40	
6 - 12 Months	0.74 - 2.40	6 - 12 Months	7.10 - 16.16	6 – 12 Months	0.70 - 7.00	





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA

CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)





A PIONEER DIAGNOSTIC CENTRE

💟 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA		
AGE/ GENDER	: 69 YRS/FEMALE	PATIENT ID	: 1763868
COLLECTED BY	:	REG. NO./LAB NO.	: 122502200019
REFERRED BY	:	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 20/Feb/2025 01:52PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - H	IARYANA	

Test Name		Value	Value Unit		Biological Reference interva	
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50	
11- 19 Years	0.35 - 1.93	11 - 19 Years	4.87- 13.20	11 – 19 Years	0.50 - 5.50	
> 20 years (Adults)	0.35 - 1.93	> 20 Years (Adults)	4.87 - 12.60	> 20 Years (Adults)	0.35-5.50	
	RECOM	MENDATIONS OF TSH LE	EVELS DURING PREC	GNANCY (µIU/mL)		
	1st Trimester			0.10 - 2.50		
	2nd Trimester			0.20 - 3.00		
	3rd Trimester			0.30 - 4.10		

INCREASED TSH LEVELS:

1. Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.

2. Hypothyroid patients receiving insufficient thyroid replacement therapy.

3.Hashimotos thyroiditis

4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.

5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

DECREASED TSH LEVELS:

1.Toxic multi-nodular goiter & Thyroiditis.

2. Over replacement of thyroid hormone in treatment of hypothyroidism.

3. Autonomously functioning Thyroid adenoma

4.Secondary pituitary or hypothalamic hypothyroidism

5. Acute psychiatric illness

6.Severe dehydration.

7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.

8. Pregnancy: 1st and 2nd Trimester



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



A PIONEER DIAGNOSTIC CENTRE

🕻 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA				
AGE/ GENDER	: 69 YRS/FEMALE	PATIENT ID	: 1763868		
COLLECTED BY	:	REG. NO./LAB NO.	: 122502200019		
REFERRED BY	:	REGISTRATION DATE	: 20/Feb/2025 11:42 AM		
BARCODE NO.	: 12507134	COLLECTION DATE	: 20/Feb/2025 11:54AM		
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 20/Feb/2025 01:52PM		
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY	- HARYANA			
Test Name	Value	Unit	Biological Reference interva		
VITAMINS VITAMIN D/25 HYDROXY VITAMIN D3					

VITAMIN D (25-HYDROXY VITAMIN D3): SERUM by CLIA (CHEMILUMINESCENCE IMMUNOASSAY) 12.3^L ng/mL DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0

INTERPRETATION:

<u>INTERFRETATION.</u>					
DEFICIENT:	< 20	ng/mL			
INSUFFICIENT:	21 - 29	ng/mL			
PREFFERED RANGE:	30 - 100	ng/mL			
INTOXICATION:	> 100	ng/mL			

1. Vitamin D compounds are derived from dietary ergocalciferol (from plants, Vitamin D2), or cholecalciferol (from animals, Vitamin D3), or by conversion of 7- dihydrocholecalciferol to Vitamin D3 in the skin upon Ultraviolet exposure.

2.25-OH--Vitamin D represents the main body resevoir and transport form of Vitamin D and transport form of Vitamin D, being stored in adipose tissue and tightly bound by a transport protein while in circulation.

3.Vitamin D plays a primary role in the maintenance of calcium homeostatis. It promotes calcium absorption, renal calcium absorption and phosphate reabsorption, skeletal calcium deposition, calcium mobilization, mainly regulated by parathyroid harmone (PTH). 4.Severe deficiency may lead to failure to mineralize newly formed osteoid in bone, resulting in rickets in children and osteomalacia in adults.

DECREASED:

1.Lack of sunshine exposure.

2.Inadequate intake, malabsorption (celiac disease)

3. Depressed Hepatic Vitamin D 25- hydroxylase activity

4. Secondary to advanced Liver disease

5.Osteoporosis and Secondary Hyperparathroidism (Mild to Moderate deficiency)

6.Enzyme Inducing drugs: anti-epileptic drugs like phenytoin, phenobarbital and carbamazepine, that increases Vitamin D metabolism.

INCREASED:

1. Hypervitaminosis D is Rare, and is seen only after prolonged exposure to extremely high doses of Vitamin D. When it occurs, it can result in severe hypercalcemia and hyperphophatemia.

CAUTION: Replacement therapy in deficient individuals must be monitored by periodic assessment of Vitamin D levels in order to prevent hypervitaminosis D

NOTE:-Dark coloured individuals as compare to whites, is at higher risk of developing Vitamin D deficiency due to excess of melanin pigment which interefere with Vitamin D absorption.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



A PIONEER DIAGNOSTIC CENTRE

🕻 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA				
AGE/ GENDER	: 69 YRS/FEMALE	PATI	ENT ID	: 1763868	
COLLECTED BY	:	REG.	NO./LAB NO.	: 122502200019	
REFERRED BY	:	REGI	STRATION DATE	: 20/Feb/2025 11:42	AM
BARCODE NO.	: 12507134	COLI	ECTION DATE	: 20/Feb/2025 11:54/	AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITU	ГЕ REP (DRTING DATE	: 20/Feb/2025 06:27F	PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBAL	A CITY - HARYAN	A		
Test Name		Value	Unit	Biological I	Reference interval
Test Name		Value	Unit	Biological I	Reference interva
Test Name	VII	Value CAMIN B12/C		Biological I	Reference interval
VITAMIN B12/COE				Biological I 200.0 - 110	
VITAMIN B12/COE by CMIA (CHEMILUMIN INTERPRETATION:-	ALAMIN: SERUM ESCENT MICROPARTICLE IMMUNOASSAY)	CAMIN B12/C	OBALAMIN pg/mL	200.0 - 110	
VITAMIN B12/COE by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS	ALAMIN: SERUM ESCENT MICROPARTICLE IMMUNOASSAY) ED VITAMIN B12	CAMIN B12/C	OBALAMIN	200.0 - 110	
VITAMIN B12/COE by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan	ALAMIN: SERUM ESCENT MICROPARTICLE IMMUNOASSAY) ED VITAMIN B12 in C	CAMIN B12/C 308.7	OBALAMIN pg/mL DECREASED VITAMIN F	200.0 - 110 812	
VITAMIN B12/COE by CMIA (CHEMILUMIN <u>INTERPRETATION:-</u> INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro	ALAMIN: SERUM ESCENT MICROPARTICLE IMMUNOASSAY) ED VITAMIN B12 hin C gen	CAMIN B12/C 308.7 1.Pregnancy 2.DRUGS:Aspi	OBALAMIN pg/mL DECREASED VITAMIN F	200.0 - 110 812	
VITAMIN B12/COE by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan	ALAMIN: SERUM ESCENT MICROPARTICLE IMMUNOASSAY) ED VITAMIN B12 hin C gen hin A	CAMIN B12/C 308.7 1.Pregnancy 2.DRUGS:Aspi 3.Ethanol Iges	OBALAMIN pg/mL DECREASED VITAMIN F rin, Anti-convulsants, (tion	200.0 - 110 812	
VITAMIN B12/COE by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan 4.Hepatocellular in	ALAMIN: SERUM ESCENT MICROPARTICLE IMMUNOASSAY) ED VITAMIN B12 hin C gen hin A jury	AMIN B12/C 308.7 1.Pregnancy 2.DRUGS:Aspi 3.Ethanol Iges 4. Contracepti	OBALAMIN pg/mL DECREASED VITAMIN F rin, Anti-convulsants, (tion ve Harmones	200.0 - 110 812	
VITAMIN B12/COE by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan	ALAMIN: SERUM ESCENT MICROPARTICLE IMMUNOASSAY) ED VITAMIN B12 hin C gen hin A jury	CAMIN B12/C 308.7 1.Pregnancy 2.DRUGS:Aspi 3.Ethanol Iges	OBALAMIN pg/mL DECREASED VITAMIN F rin, Anti-convulsants, (tion ve Harmones rsis	200.0 - 110 812	

3. The body uses its vitamin B12 stores very economically, reabsorbing vitamin B12 from the ileum and returning it to the liver; very little is excreted.
4. Vitamin B12 deficiency may be due to lack of IE secretion by gastric mucesa (eq. gastroctomy, gastric atrentw) or intestinal malabsorbing vitamin B12 from the ileum and returning it to the liver; very little is

4. Vitamin B12 deficiency may be due to lack of IF secretion by gastric mucosa (eg, gastrectomy, gastric atrophy) or intestinal malabsorption (eg, ileal resection, small intestinal diseases).

5. Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of proprioception, poor coordination, and affective behavioral changes. These manifestations may occur in any combination; many patients have the neurologic defects without macrocytic anemia.

6.Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states.

7.Follow-up testing for antibodies to intrinsic factor (IF) is recommended to identify this potential cause of vitamin B12 malabsorption. **NOTE:**A normal serum concentration of vitamin B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for vitamin B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum vitamin B12 concentrations are normal.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

TEST PERFORMED AT KOS DIAGNOSTIC LAB. AMBALA CANTT



【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA			
AGE/ GENDER	: 69 YRS/FEMALE]	PATIENT ID	: 1763868
COLLECTED BY	:	1	REG. NO./LAB NO.	: 122502200019
REFERRED BY	:	1	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134		COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INST	TTUTE I	REPORTING DATE	: 20/Feb/2025 04:11PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AM	BALA CITY - HAR	YANA	
Test Name		Value	Unit	Biological Reference interval
		CLINICAL I	PATHOLOGY	
	URINE ROU	UTINE & MICI	ROSCOPIC EXAMIN	ATION
PHYSICAL EXAMIN	NATION			
QUANTITY RECIEV by DIP STICK/REFLEC	ED tance spectrophotometry	10	ml	
COLOUR		PALE YELI	LOW	PALE YELLOW
TRANSPARANCY	TANCE SPECTROPHOTOMETRY	CLEAR		CLEAR
SPECIFIC GRAVITY		1.01 P		1.002 - 1.030
CHEMICAL EXAMI	NATION			
•	TANCE SPECTROPHOTOMETRY	ALKALINE		
•	TANCE SPECTROPHOTOMETRY	NEGATIVE		NEGATIVE (-ve)
-	TANCE SPECTROPHOTOMETRY	NEGATIVE 7.5	. (-ve)	NEGATIVE (-ve) 5.0 - 7.5
pH by DIP STICK/REFLEC	TANCE SPECTROPHOTOMETRY	7.5		5.0 - 7.5
BILIRUBIN		NEGATIVE	: (-ve)	NEGATIVE (-ve)
NITRITE	TANCE SPECTROPHOTOMETRY	NEGATIVE	L (-ve)	NEGATIVE (-ve)
UROBILINOGEN	TANCE SPECTROPHOTOMETRY	NOT DETE	CTED EU/dL	0.2 - 1.0
	TANCE SPECTROPHOTOMETRY	NEGATIVE		NEGATIVE (-ve)
•	TANCE SPECTROPHOTOMETRY	NEGATIVE		NEGATIVE (-ve)
,	TANCE SPECTROPHOTOMETRY	NEGATIVE	. (-ve)	NEGATIVE (-ve)
MICROSCOPIC EXA RED BLOOD CELLS		NEGATIVE	C(-ve) /HPF	0 - 3



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE



A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. NEELAM KHANNA		
AGE/ GENDER	: 69 YRS/FEMALE	PATIENT ID	: 1763868
COLLECTED BY	:	REG. NO./LAB NO.	: 122502200019
REFERRED BY	:	REGISTRATION DATE	: 20/Feb/2025 11:42 AM
BARCODE NO.	: 12507134	COLLECTION DATE	: 20/Feb/2025 11:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 20/Feb/2025 04:11PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY -	HARYANA	

Test Name	Value	Unit	Biological Reference interval
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
PUS CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	4-5	/HPF	0 - 5
EPITHELIAL CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	3-4	/HPF	ABSENT
CRYSTALS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
CASTS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
BACTERIA by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
OTHERS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
TRICHOMONAS VAGINALIS (PROTOZOA) by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	ABSENT		ABSENT

*** End Of Report



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

